Strong Buy
Average AnalystStrong Buy
Top AnalystSlightly Bearish
Stock Target AdvisorStrong Buy
Average UserUSD 21.86
+0.65 (+3.06%)
USD 1.57B
2.54M
USD 22.08(+0.99%)
Based on the Travere Therapeutics Inc stock forecast from 13 analysts, the average analyst target price for Travere Therapeutics Inc is USD 22.08 over the next 12 months. Travere Therapeutics Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Travere Therapeutics Inc is Slightly Bearish, which is based on 3 positive signals and 7 negative signals. At the last closing, Travere Therapeutics Inc’s stock price was USD 21.86. Travere Therapeutics Inc’s stock price has changed by +3.85% over the past week, +16.84% over the past month and +152.13% over the last year.
Target Price Action | Rating Action | Analyst | Rating | Price | Date |
---|
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.
This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.
The stock is trading high compared to its peers median on a price to book value basis.
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
The company had negative total cash flow in the most recent four quarters.
The company had negative total free cash flow in the most recent four quarters.
This stock has shown below median revenue growth in the previous 5 years compared to its sector
The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.